Clinical Trials Logo

Carcinoma, Hepatocellular clinical trials

View clinical trials related to Carcinoma, Hepatocellular.

Filter by:

NCT ID: NCT06365034 Recruiting - Clinical trials for Carcinoma, Hepatocellular

Study on the Efficacy and Safety of Conversion Therapy in Patients With Initially Unresectable Hepatocellular Carcinoma

Start date: March 1, 2024
Phase:
Study type: Observational

To evaluate the efficacy and safety of conversion therapy in patients with initially unresectable hepatocellular carcinoma (uHCC).

NCT ID: NCT06364007 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

Start date: March 3, 2024
Phase: Phase 2
Study type: Interventional

The treatment options for unresectable HCC have rapidly developed, and immunotherapy has shown significant survival benefits in hepatocellular carcinoma. The STRIDE regimen of Single Tremelimumab (high, priming 300-mg dose) Regular Interval Durvalumab (1500 mg every 4 weeks) improved OS vs sorafenib in pts with unresectable HCC. In Asian region, HAIC is applied for HCC patients who are not suitable for surgical resection or local ablation treatment. Retrospective studies suggested a potent antitumor effect and survival benefit of HAIC plus programmed death-1 inhibitor and Lenvatinib. This phase II study was aimed to evaluate the efficacy and safety of STRIDE plus lenvatinib, given concurrently with HAIC in pts with unresectable HCC.

NCT ID: NCT06363825 Recruiting - Clinical trials for Advanced Hepatocellular Carcinoma

A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma

Start date: April 12, 2024
Phase: Phase 2
Study type: Interventional

To evaluate the efficacy and safety of TAE+HAIC combined with camrelizumab and apatinib in the treatment of advanced liver cancer with high tumor load

NCT ID: NCT06363006 Recruiting - Clinical trials for Hepatocellular Carcinoma

Combination of Cardonizumab Injection and TKI Second Line Therapy for Advanced Hepatocellular Cancer

Start date: March 11, 2024
Phase: Phase 1
Study type: Interventional

The goal of this clinical trial is to evaluate the efficacy and safety of cardonilizumab injection combined with TKI in second-line treatment of advanced hepatocellular carcinoma. The main questions it aims to answer are: - Objective response rate (ORR) for evaluation - Disease Control Rate (DCR); Duration of relief (DoR); Progression free survival (PFS); Total survival time (OS); Safety。

NCT ID: NCT06360042 Recruiting - Clinical trials for Unresectable Hepatocellular Carcinoma

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

This is a multicenter, randomized, open-label clinical study to evaluate the efficacy and safety of Adebrelimab plus Apatinib (cohort 1), or Adebrelimab plus Bevacizumab (cohort 2), or Camrelizumab plus Apatinib (cohort 3) as first-line treatment of unresectable HCC.

NCT ID: NCT06355700 Recruiting - Clinical trials for Hepatocellular Carcinoma

Hepatocellular Carcinoma Liver Organoids

HELIO
Start date: June 15, 2023
Phase: N/A
Study type: Interventional

The goal of this interventional study is to create hepatocellular carcinoma organoids from liver bioptic samples of individuals with hepatocellular carcinoma. The main questions it aims to answer are: - the feasibility of hepatocellular carcinoma organoids integrated with host gut microbiota and peripheral blood mononuclear cells - the molecular pattern of the organoid tumor microenvironment - the in vitro therapeutic response of hepatocellular carcinoma organoids

NCT ID: NCT06354387 Recruiting - Clinical trials for Hepatocellular Carcinoma

Alectinib in Combination With Nivolumab in the Treatment of Recurrent or Refractory HCC Patients Guided With Serum RNase1 and Tumor Expression of PD-L1

Start date: February 16, 2022
Phase: Phase 1
Study type: Interventional

Hepatocellular carcinoma (HCC) is the fourth most common cause of cancer-related death and the second most deadly malignancy in Taiwan. Despite decades' intensive studies, surgery and local-regional chemo-embolization, radio-frequency ablation or radiation therapy remain the mainstay of HCC treatments.

NCT ID: NCT06349642 Recruiting - Clinical trials for Metastatic Malignant Solid Neoplasm

Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform

CYBRID-04
Start date: April 24, 2024
Phase:
Study type: Observational

The primary purpose of this study is to determine the sensitivity of CYBRID Score for predicting in-vivo clinical response based on surgical response or RECIST 1.1 for neoadjuvant and locally advanced/metastatic patients, respectively. The secondary purposes is to determine the sensitivity of the CYBRID Score for predicting in-vivo clinical response based on surgical response or RECIST 1.1 for neoadjuvant and locally advanced/metastatic patients, respectively.

NCT ID: NCT06342414 Recruiting - Clinical trials for Hepatocellular Carcinoma

An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer

ELUCIDATE
Start date: March 15, 2024
Phase:
Study type: Observational

It is sometimes difficult to precisely understand whether a primary liver cancer is a hepatocellular carcinoma or a cholangiocarcinoma. The researchers will develop and validate a liquid biopsy, based on exosomal content analysis and powered by machine learning, to help clinicians differentiate these two cancers before surgery.

NCT ID: NCT06333561 Recruiting - Clinical trials for Hepatocellular Carcinoma

HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma

Start date: January 1, 2021
Phase:
Study type: Observational

Hepatic arterial infusion chemotherapy (HAIC) plus lenvatinib and programmed cell death protein-1 (PD-1) inhibitor have shown promising results for advanced hepatocellular carcinoma (HCC). However, the evidence for infiltrative is limited. In this study, we aimed to describe the efficacy and safety of lenvatinib and PD-1 inhibitor with HAIC plus lenvatinib for infiltrative HCC.